In acute myeloid leukemia (AML), the Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes. Recently, a new and recurrent juxtamembrane deletion mutation (p.Q569Vfs*2) resulting in a truncated receptor was identified. The mutated receptor is expressed on the cell surface and still binds its ligand but loses the ability to activate ERK signaling. FLT3 p.Q569fs-expressing Ba/F3 cells show no proliferation after ligand stimulation. Furthermore, coexpressed with the FLT3 wild-type (WT) receptor, the truncated receptor suppresses stimulation and activation of the WT receptor. Thus, FLT3 p.Q569Vfs*2, to our knowledge, is the first FLT3 mutation with a dominant negative effect on the WT receptor.
The Fms-like tyrosine kinase 3 (FLT3) gene encodes a receptor tyrosine kinase (RTK), which is mostly expressed on hematopoietic progenitor cells and enables these cells to proliferate and differentiate. The high prevalence of activating mutations of the FLT3 gene in acute myeloid leukemia (AML) indicates the importance of FLT3 for physiological hematopoiesis 1, 2 . The most common alterations occur in two functional domains of the receptor. Internal tandem duplications (ITD) disrupt the autoinhibitory function of the juxtamembrane domain and convey ligand-independent phosphorylation and activation of FLT3 3 . Point mutations within the activation loop of the tyrosine kinase domain (TKD) mark another class of gain-of-function FLT3 mutations 4 . Both, ITD and TKD mutations, lead to a constitutive activation of downstream signaling pathways such as the ERK and STAT5 pathway 3, 4 . With the technical improvement of sequencing methods over recent years the number of novel identified FLT3 mutations is increasing. However, the evaluation of functional relevance remains difficult, since the mutation's position in a mutational hotspot or in an important functional receptor domain alone cannot predict its oncogenic potential 5 . In this study we functionally characterized a novel frameshift deletion mutation in the juxtamembrane region (JM) of FLT3 found in a relapsed patient with AML. We investigated the functional properties of the truncated FLT3 receptor since truncated variants of other receptors have been shown to promote hematopoietic malignancies [6] [7] [8] [9] .
Materials and Methods

FLT3 mutation analysis.
A patient was referred to our hospital for treatment of AML relapse. Mononuclear cells were isolated from bone marrow aspirates and conventional cytogenetic and mutational analyses were performed in accordance with described protocols 10 . Sequencing of the FLT3 gene was performed using Sanger sequencing. The FLT3 variant was described according to the guidelines of the Human Genome Variation Society (HGVS) (http://varnomen.hgvs.org). Mutations in further AML-related genes were analyzed using a targeted, multiplexed amplicon resequencing approach as previously described 10 . The experimental protocols were approved by the Institutional Review Board of the Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany and written informed consent was obtained in accordance with the Declaration of Helsinki. The methods were performed in accordance with the approved guidelines. Cell culture and reagents. The Ba/F3, Hek-293T, and WEHI-3B cell lines were obtained from DSMZ (Braunschweig, Germany), the U2OS cell line from ATCC (Wesel, Germany) and cultured according to the supplier's recommendation. The retroviral packaging cell line Phoenix eco was purchased from Orbigen (San Diego, CA, USA). Recombinant human FLT3 ligand (FL) was obtained from PromoKine (Heidelberg, Germany), recombinant murine IL-3 from ImmunoTools (Friesoythe, Germany) and AC220 was obtained form Selleck Chemicals (Houston, TX, USA).
Generation of cell lines. The FLT3 p.Q569Vfs*2 and the FLAG FLT3 p.Q569Vfs*2 cDNA were synthesized by GENEART (Life Technologies, Regensburg, Germany) and subcloned into the MSCV-IRES-eYFP retroviral expression vector. The empty vector, MSCV-IRES-eGFP-FLT3-WT, and MSCV-IRES-eGFP-FLT3-W51 have been described previously 11 . For the stable transduction of Ba/F3 cells the retroviral supernatant of Phoenix eco cells was used 11 . Stable expression of the receptor was confirmed by real time-PCR, Western blot, immunoprecipitation and flow cytometry as described elsewhere 11, 12 . The following antibodies were used as recommended by the manufacturer: anti FLAG (M2), alpha-Tubulin (T6199), goat anti rabbit secondary antibody from Sigma-Aldrich (St. Louis, MO, USA), FLT3 (SF1.340, S-18), phospho-tyrosine (PY99), goat anti mouse and goat anti rat secondary antibodies from Santa Cruz Biotechnology (CA, USA), ERK and phospho-ERK (Thr202/Tyr204) from Cell Signaling Technology (Danvers, MA, USA). The FLT3-antibody (4B12) was provided by Dr. Elisabeth Kremmer (Helmholtz Center Munich).
Cell proliferation assay. 4 × 10
4 /mL Ba/F3 cells were cultured in the presence or absence of 10 ng IL-3 and 50 ng FL for 72 hours. Viable cells were counted by trypan blue exclusion using the cell viability analyzer Vi-CELL AS (Beckman Coulter, Krefeld, Germany) 11 .
FL binding assay. Binding of the FL was analyzed using the Fluorokine biotinylated human FL kit (NFFK0)
and streptavidin-allophycocyanin (APC) (F0050) (R&D Systems, Minneapolis, MN, USA) according to the supplier's recommendations. As a negative staining control cells were stained with biotinylated soybean trypsin inhibitor. To confirm staining specificity cells were incubated with unbiotinylated FL in parallel.
Immunofluorescent staining. U2OS cells were transiently transfected using the PolyFect transfection reagent (QIAGEN, Hilden, Germany). 50,000 cells were seeded on coverslips one day prior transfection. For transfection 1.5 μ g plasmid DNA, 5 μ L of transfection reagent and Opti-MEM Reduced Serum Medium (Thermo Fisher Scientific, Braunschweig, Germany) were used. The medium was changed six hours later. Glycoconjugates were stained 48 hours post-transfection using anti-wheat germ agglutinin (WGA)-488 fluorescein conjugate (1:1000; Life Technologies, Carlsbad, CA, USA) for 10 minutes. Thereafter cells were fixed on ice for 10 minutes using pre-cooled methanol and blocked for 1 hour with 2% BSA in DPBS. Cells were then incubated with monoclonal mouse or polyclonal rabbit FLT3 (SF1.340, S-18) antibody (1:200; Santa Cruz Biotechnology) for 1 hour, followed by washing with DPBS-T (0.1% Tween 20; Carl Roth, Karlsruhe, Germany). Secondary antibody incubation was performed for 1 hour with anti-mouse IgG (H + L), F (ab') 2 fragment Alexa Fluor 594 Conjugate (1:500; Cell Signaling Technology). For counterstaining 1 μ g/mL 4' ,6-diamidino-2-phenylindole (DAPI) was used (Sigma-Aldrich), followed by mounting. Specimens were finally analyzed utilizing a confocal fluorescence laser scanning system (TCS SP5 II; Leica, Wetzlar, Germany). For image acquisition and processing we used the LAS AF Lite Software (Leica).
Results
The FLT3 mutation (p.Q569Vfs*2), present only at relapse, results in a truncated FLT3 receptor lacking essential parts for autophosphorylation. The FLT3 mutation (FLT3 p.Q569Vfs*2) was found during routine diagnostics in a patient with relapsed AML and 15% blasts in the bone marrow (Supplemental Table S1 ). Fragment size analysis from cDNA showed the FLT3 wild-type (WT) peak and an additional smaller and shorter fragment (Fig. 1a) , indicating a smaller proportion of cells with an alternative FLT3 transcript. The allele frequency of the detected mutation could not be determined as there was no patient gDNA material available.
At the time point of first diagnosis, this fragment was not present (Supplemental Table S1 ). At the time point of initial diagnosis, the major leukemic clone carried an IDH2 mutation with an allele frequency of 20.4%. NPM1c was present only in a subfraction (7.2% allele frequency) and FLT3-ITD/TKD mutations were undetectable (Supplemental Table S1 ). By Sanger sequencing a deletion in the FLT3 gene of eight base pairs leading to a frameshift followed by a premature stop codon was identified (Fig. 1b) . The mutant is predicted to result in a truncated FLT3 protein, consisting of 570 amino acids and lacking the intracellular parts essential for autophosphorylation of the receptor and downstream signal transduction (Fig. S1 ). Due to lack of adequate patient material, it was not possible to finally prove the expression of the truncated protein in the patient's bone marrow. To characterize p.Q569Vfs*2 sequence. (c) Phoenix eco cells were transfected with FLAG-tagged FLT3 WT and FLAG-tagged FLT3 p.Q569Vfs*2. After cell lysis the FLT3 protein was immunoprecipitated from whole cell lysates with an N-terminal FLT3 antibody (SF1.340). After blotting the FLAG-tagged FLT3 was detected with an FLAG M2 antibody. One representative experiment is shown. the functional consequences of the deletion mutation we thus generated Ba/F3 cells stably expressing FLT3 WT and FLT3 p.Q569Vfs*2. In Western Blot analysis we observed a band of lower molecular weight (110 kD) in FLT3 p.Q569Vfs*2-expressing cells in comparison to the WT receptor (140/160 kDa), confirming the expression of a truncated protein (Fig. 1c,d , the full-length blots are shown in supplemental Fig. S4a-c) .
The loss of function FLT3 p.Q569Vfs*2 mutant suppresses FLT3 WT in a dominant negative manner by forming heterodimers with the WT FLT3 receptor. FLT3 p.Q569Vfs*2 receptor expression on the cell surface was confirmed by flow cytometry and immunofluorescent staining (Fig. 1e, Supplemental Fig. S2 ) and binding of FL by FL binding assays with biotinylated FL (Fig. 2a) . After adding of unbiotinylated FL to the sample, the binding capacity for biotinylated FL decreased in a dose dependent manner indicating the specificity of the FL binding assay (Supplemental Fig. S3) . By immunoprecipitation the truncated FLT3 protein in double-transfected Hek-293T cells, and immunoblot against a C-terminal FLT3 epitope, heterodimerisation of the truncated and the wildtype FLT3 receptor became detectable (Fig. S5b) . In contrast to FLT3 WT, FLT3 p.Q569Vfs*2-expressing Ba/F3 cells did not proliferate after FL stimulation (Fig. 2b) . Furthermore, coexpression of WT and mutant FLT3 receptor also abolished the WT receptor's proliferative effect on Ba/F3 cells when stimulated with FL (Fig. 2b) . This observation was confirmed by analyzing the downstream signaling pathway. Stimulation of FLT3 WT-expressing cells with FL led to strong FLT3 and subsequent ERK phosphorylation which were absent in FLT3 p.Q569Vfs*2-expressing and FLT3 p.Q569Vfs*2/FLT3 WT-coexpressing cells, respectively (Fig. 2c , the full-length blots are shown in supplemental Fig. S4d,e and Fig. S5c,d) .
In order to address a possible growth advantage of the FLT3 p.Q569Vfs*2-expressing cells, we performed proliferation assays in Ba/F3 cells treated with the highly potent FLT3 inhibitor AC220 in two different concentrations. Neither the FLT3 p.Q569Vfs*2 cells nor the double-transduced cells had a growth advantage under the chosen conditions (see supplemental Fig. S5a ).
Discussion
AML-specific mutations within the FLT3 gene have been of high interest and were studied in detail over the past decades. In contrast to the highly prevalent activating mutations the impact of receptor truncating mutations in FLT3 remains largely unknown, especially regarding their proliferative activity. To our knowledge, this is the first study to functionally characterize a patient derived loss-of-function FLT3 mutation resulting in a dominant negative effect on the WT receptor. Our analysis demonstrated that the truncated FLT3 receptor lack both TKDs that are crucial for signal transduction, thus being unable to activate ERK phosphorylation and proliferation upon ligand binding. These effects were dominant negative on FLT3 WT in cells coexpressing both FLT3 WT and p.Q569Vfs*2.
In analogy, kinase-negative or truncated EGF receptors can exert a dominant negative effect on WT receptors by inhibiting the tyrosine kinase activity and suppressing the mitogenic response of WT receptors through heterodimerisation 13, 14 . However, the receptor truncation does not always imply a loss of function. Alterations of the CSF3R gene, which lead to a truncated cytoplasmic tail, showed an activating and hyperresponsive phenotype and have been linked to the development of AML, chronic myeloid and neutrophilic leukemia 6, 7 . Similary, truncations in the extracellular domain of the TrkA receptor ("Delta TrkA") constitutively activate the receptor in fibroblast and epithelial cell lines 8, 9 . The loss-of-function phenotype of FLT3 p.Q569Vfs*2 suggests that the patient's AML blasts proliferate independently of FLT3 kinase activity. We cannot exclude that FLT3 p.Q569Vfs*2 is a passenger mutation in a mutational hotspot region of the FLT3 gene and does not influence leukemogenesis. However, the same somatic deletion mutation has been reported recently as a somatic and recurrent mutation, detected in two out of 6843 unselected AML patients resulting in a frequency of 0.03% 15 . It is tempting to speculate that a leukemic cell may benefit from truncating FLT3 mutations through escape from the FLT3 receptor mediated growth regulation. Functional characterization of FLT3 mutations nevertheless is of major importance to identify driver mutations, validate therapeutic targets and analyze the mechanisms of receptor interaction and activation. Our study shows that mutations of FLT3 do not always accompany a gain of function and functional relevance has to be investigated on an individual basis.
